These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33040627)

  • 1. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
    Lorusso D; Ceni V; Muratore M; Salutari V; Nero C; Pietragalla A; Ciccarone F; Carbone V; Daniele G; Scambia G
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):445-453. PubMed ID: 33040627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
    Maiorano BA; Lorusso D; Maiorano MFP; Ciardiello D; Parrella P; Petracca A; Cormio G; Maiello E
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
    Musacchio L; Cicala CM; Camarda F; Ghizzoni V; Giudice E; Carbone MV; Ricci C; Perri MT; Tronconi F; Gentile M; Salutari V; Scambia G; Lorusso D
    ESMO Open; 2022 Aug; 7(4):100536. PubMed ID: 35849879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
    Miller RE; Lewis AJ; Powell ME
    Br J Radiol; 2021 Dec; 94(1128):20210002. PubMed ID: 33882241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
    Lorusso D; Fontanella C; Maltese G; Lepori S; Tripodi E; Bogani G; Raspagliesi F
    Expert Opin Drug Saf; 2017 Jun; 16(6):687-696. PubMed ID: 28471247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of ovarian cancer including immune check point inhibitor.
    Kim JY; Cho CH; Song HS
    Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in gynecological cancers.
    Lorusso D; Ceni V; Daniele G; Pietragalla A; Salutari V; Muratore M; Nero C; Ciccarone F; Scambia G
    Explor Target Antitumor Ther; 2021; 2(1):48-64. PubMed ID: 36046088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advancements of antiangiogenic combination therapies in ovarian cancer.
    An D; Banerjee S; Lee JM
    Cancer Treat Rev; 2021 Jul; 98():102224. PubMed ID: 34051628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
    Lee EK; Konstantinopoulos PA
    Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic applications of PARP inhibitors in ovarian cancer.
    Xie H; Wang W; Xia B; Jin W; Lou G
    Biomed Pharmacother; 2020 Jul; 127():110204. PubMed ID: 32422564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 12. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
    Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 15. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    Goncalves A; Mezni E; Bertucci F
    Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for platinum-resistant ovarian cancer.
    Bogani G; Lopez S; Mantiero M; Ducceschi M; Bosio S; Ruisi S; Sarpietro G; Guerrisi R; Brusadelli C; Dell'Acqua A; Di Donato V; Raspagliesi F
    Gynecol Oncol; 2020 Aug; 158(2):484-488. PubMed ID: 32518015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the application of immune checkpoint inhibitors in gynecological tumors.
    Zou Y; Xu Y; Chen X; Zheng L
    Int Immunopharmacol; 2023 Apr; 117():109774. PubMed ID: 37012881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
    Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
    Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
    Nero C; Ciccarone F; Pietragalla A; Duranti S; Daniele G; Salutari V; Carbone MV; Scambia G; Lorusso D
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors.
    Zhou L; Wan Y; Zhang L; Meng H; Yuan L; Zhou S; Cheng W; Jiang Y
    Biomed Pharmacother; 2024 Jun; 175():116733. PubMed ID: 38754267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.